Baillie Gifford & Co. Cuts Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Baillie Gifford & Co. reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 14,486 shares of the company’s stock after selling 390 shares during the period. Baillie Gifford & Co.’s holdings in Medpace were worth $4,813,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in shares of Medpace in the fourth quarter valued at approximately $30,000. Stone House Investment Management LLC purchased a new stake in shares of Medpace in the third quarter valued at approximately $33,000. Ashton Thomas Securities LLC purchased a new stake in shares of Medpace in the third quarter valued at approximately $37,000. Capital Performance Advisors LLP purchased a new stake in shares of Medpace in the third quarter valued at approximately $46,000. Finally, True Wealth Design LLC grew its position in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Up 0.2 %

NASDAQ:MEDP opened at $340.77 on Wednesday. The stock’s fifty day moving average is $343.26 and its two-hundred day moving average is $347.75. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The stock has a market capitalization of $10.59 billion, a price-to-earnings ratio of 29.84, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on MEDP. Robert W. Baird upped their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. TD Cowen dropped their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.